Streetbeat News

Analyst Ratings

TSX:DND

BMO Capital analyst Thanos Moschopoulos has maintained an 'Outperform' rating on Dye & Durham, but lowered the price target from C$25 to C$18.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:34 pm

CHGG

BMO Capital analyst Jeffrey Silber has maintained a 'Market Perform' rating on Chegg (NYSE:CHGG) but lowered the price target from $12 to $10.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:33 pm

IWM

XLC

The article discusses the uncertainty in the market, questioning whether it is a bull market or a bear market rally. It mentions the dip in the market, the reduction of the end-of-year target for the S&P 500 by Fundstrats Tom Lee, and the unstable inflation situation. The article also highlights the performance of the Russell 2000 ETF (IWM) and the SPDR ETF (XLC), suggesting a low risk appetite and potential continuation to the downside.

Portfolio Pulse from Thrash Capital

October 31, 2023 | 1:30 pm

VFC

V.F. Corp (NYSE:VFC) reported mixed Q2 results, beating sales estimates but missing on earnings per share. The company also announced a transformation program, withdrew its full-year guidance, and expects a difficult wholesale environment ahead in the U.S. Multiple analysts lowered their price targets for VFC following the results.

Portfolio Pulse from Adam Eckert

October 31, 2023 | 1:26 pm

SFM

Sprouts Farmers Market (NASDAQ:SFM) reported Q3 earnings of $0.65 per share, beating the analyst consensus estimate of $0.62 by 4.84%. The company also reported quarterly sales of $1.71 billion, surpassing the analyst consensus estimate of $1.68 billion by 1.96%. Both earnings and sales show an increase compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:23 pm

XLO

Xilio Therapeutics, Inc. (NASDAQ:XLO) will host a virtual investor conference call and webcast on November 6, 2023, to review progress across its pipeline of tumor-activated molecules, including Phase 1/2 clinical data for XTX202. The data will be presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:22 pm

CYBN

HC Wainwright & Co. analyst Patrick Trucchio has reiterated a 'Buy' rating on Cybin (AMEX:CYBN) and maintained a $10 price target.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:22 pm

IOVA

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has announced the publication of abstracts for poster presentations reporting clinical data and trial design for tumor infiltrating lymphocyte (TIL) therapies at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting. The data includes a four-year analysis of pooled Cohorts 2 and 4 of the C-144-01 trial, which reports the longest follow-up data on lifileucel treatment outcomes in patients with anti–PD-1–refractory advanced melanoma treated with TIL therapy.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:20 pm

KTRA

Kintara Therapeutics (NASDAQ:KTRA) announced that its GBM AGILE study showed that VAL-083 did not perform better than the current standards of care in glioblastoma. As a result, the company is suspending the development of VAL-083 and shifting its focus to its REM-001 program and other strategic opportunities. The company also plans to conduct a review of potential strategic opportunities to maximize shareholder value. Kintara expects to enroll the first subject in a 15-patient CMBC study around the end of 2023, which is expected to be covered by a $2 million grant from the NIH.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:18 pm

LMDX

PETS

PINS

RNAZ

SRPT

WOLF

Several stocks are experiencing significant pre-market movements. LumiraDx Limited (LMDX) surged 38.8% after a Nasdaq delisting determination. TransCode Therapeutics (RNAZ) gained 30.1% after withdrawing a public offering. Pinterest (PINS) rose 16.5% following better-than-expected Q3 results and guidance. Wolfspeed (WOLF) rose 14.9% after Q1 earnings. On the downside, Sarepta Therapeutics (SRPT) fell 45.4% after reporting topline results from a pivotal study. PetMed Express (PETS) dipped 26.8% after weaker-than-expected Q2 sales.

Portfolio Pulse from Lisa Levin

October 31, 2023 | 1:15 pm